Alps Advisors Inc. Buys Shares of 5,490 Incyte Corporation $INCY

Alps Advisors Inc. purchased a new position in Incyte Corporation (NASDAQ:INCY) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,490 shares of the biopharmaceutical company’s stock, valued at approximately $466,000.

Other hedge funds also recently bought and sold shares of the company. denkapparat Operations GmbH raised its position in Incyte by 46.1% during the second quarter. denkapparat Operations GmbH now owns 11,292 shares of the biopharmaceutical company’s stock valued at $769,000 after purchasing an additional 3,564 shares in the last quarter. LBP AM SA boosted its holdings in shares of Incyte by 33.6% in the 3rd quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company’s stock worth $20,245,000 after purchasing an additional 59,974 shares in the last quarter. Rakuten Investment Management Inc. purchased a new position in shares of Incyte in the 3rd quarter worth about $14,646,000. Massachusetts Financial Services Co. MA increased its position in shares of Incyte by 38.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company’s stock valued at $32,873,000 after purchasing an additional 108,645 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Incyte by 28.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 106,789 shares of the biopharmaceutical company’s stock valued at $9,309,000 after buying an additional 23,954 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on INCY. Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. Morgan Stanley set a $102.00 price objective on shares of Incyte in a report on Wednesday. Truist Financial set a $103.00 price objective on shares of Incyte in a research note on Wednesday, December 24th. Royal Bank Of Canada decreased their target price on shares of Incyte from $95.00 to $92.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $90.00 price target on shares of Incyte in a research note on Thursday, January 8th. Nine equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $103.94.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Insiders Place Their Bets

In other news, EVP Steven H. Stein sold 20,105 shares of Incyte stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $102.51, for a total value of $2,060,963.55. Following the sale, the executive vice president directly owned 63,129 shares in the company, valued at approximately $6,471,353.79. This trade represents a 24.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael James Morrissey sold 54,008 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $97.29, for a total value of $5,254,438.32. Following the transaction, the executive vice president directly owned 31,830 shares in the company, valued at $3,096,740.70. This trade represents a 62.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 95,225 shares of company stock worth $9,519,745 in the last quarter. 17.80% of the stock is currently owned by company insiders.

Incyte Trading Up 0.3%

NASDAQ:INCY opened at $101.10 on Friday. The firm has a market capitalization of $20.12 billion, a P/E ratio of 15.77, a P/E/G ratio of 0.60 and a beta of 0.82. The company has a quick ratio of 3.13, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $101.73 and a 200 day moving average of $94.07. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $112.29.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The firm had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. Incyte’s revenue was up 27.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.43 EPS. On average, research analysts predict that Incyte Corporation will post 4.86 earnings per share for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.